Subscribe
shutterstock_1953872299_marlon_trottmann
Marlon Trottmann / Shutterstock.com
19 May 2022Big PharmaAlex Baldwin

Roche and Bluebird settle ‘Spark’ TM suit

Roche subsidiary Spark Therapeutics has settled a lawsuit with rival gene-therapy company Bluebird Bio, which it had accused of infringing its “Spark” trademarks when marketing treatment for sickle-cell disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Exhaustion and parallel trade: what’s next for pharma TMs?
1 December 2022   As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights.
Medtech
English court says Roche did not infringe insulin pump patents
13 July 2021   The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Big Pharma
Exhaustion and parallel trade: what’s next for pharma TMs?
1 December 2022   As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights.
Medtech
English court says Roche did not infringe insulin pump patents
13 July 2021   The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

More on this story

Big Pharma
Exhaustion and parallel trade: what’s next for pharma TMs?
1 December 2022   As the ‘UK+’ exhaustion regime is set to continue for now, Rebecca Anderson-Smith of Mewburn Ellis explores how pharma firms should protect their rights.
Medtech
English court says Roche did not infringe insulin pump patents
13 July 2021   The English High Court has cleared Roche of patent infringement claims over its line of insulin pumps but shot down the pharma giant’s attempt to invalidate the plaintiff’s patent.
Big Pharma
Amgen asks SCOTUS to reject Roche petition
14 April 2021   Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims